Loading
Alector, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Wehner David M., was filed 03 Feb 2020.
Insider Decl.
466
Thresholds
n/a
Buy Volume
€7M
4 ops. · all time
Sell Volume
€155M
236 ops. · all time
Who traded when
BuySaleGrace Wong-Sarad13 sales
Arnon Rosenthal8 sales
Kenkare-Mitra Sara5 sales
Neil Lindsay Berkley5 sales
Grasso Marc3 sales
Romano Gary2 sales
+2 other insiders
Since the insiders bought
- -36.0%Entry US$30.18 · Close at T+365 US$19.33
- +72.9%Entry US$17.50 · Close at T+365 US$30.26
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Alector, Inc. Hold (neutral), based on 5 analysts. Average price target: US$3.90.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.97
Analyst consensus
5 analystsHold
US$1.00Target US$3.90(+98%)US$8.00
Income statement
RevenueUS$21M
EBITDA-US$146.3M-695% margin
Net income-US$142.9M-679.2% margin
Valuation
PER (forward)-2.7x
P/Book6.4x
Beta0.62
Balance sheet & cash
Market capUS$220M
Total debtUS$36.2M
Free Cash Flow-US$184.1M
Debt / Equity333%
Profitability & ownership
ROE-385.1%
ROA-27.6%
% insiders7.4%
% institutions70.2%
Last declaration on 15 October 2026
Declarations466 total
217,500 shares0Common StockSEC:0001193125-26-422869:0
55,555 shares0Common StockSEC:0001193125-26-422867:0
44,567 shares0Common StockSEC:0001193125-26-422868:0
3,625 shares@ US$2.50880.0041% mcap58.1% of flowCommonSEC144:0001950047-26-009118
29,251 shares@ US$2.66480.035% mcap30.1% of flowCommon StockSEC:0001193125-26-383856:0
72,606 shares@ US$2.66470.087% mcap1.8% of flowCommon StockSEC:0001193125-26-383857:0
656 shares@ US$2.750.0008% mcap1.6% of flowCommon StockSEC:0001193125-26-383858:0
5,165 shares@ US$2.66550.0062% mcap12.2% of flowCommon StockSEC:0001193125-26-383858:1
3,625 shares@ US$2.50880.0041% mcap8.0% of flowCommon StockSEC:0001193125-26-383858:2
32,103 shares@ US$2.400.035% mcap100.0% of flowCommon StockSEC144:0001193125-26-379020
79,702 shares@ US$2.400.086% mcap100.0% of flowCommon StockSEC144:0001193125-26-379022
5,662 shares@ US$2.400.0061% mcap100.0% of flowCommon StockSEC144:0001193125-26-379023
1,050,000 shares0Common StockSEC:0001193125-26-361376:0
350,000 shares0Common StockSEC:0001193125-26-361376:1
350,000 shares0Common StockSEC:0001193125-26-361376:2
350,000 shares0Common StockSEC:0001193125-26-361376:3
20,000 shares0Common StockSEC:0001193125-26-299678:0
28,700 sharesCommon StockSEC:0001193125-26-274120:0
28,700 sharesCommon StockSEC:0001193125-26-274123:0
28,700 sharesCommon StockSEC:0001193125-26-274124:0
28,700 sharesCommon StockSEC:0001193125-26-274128:0
28,700 sharesCommon StockSEC:0001193125-26-274131:0
28,700 sharesCommon StockSEC:0001193125-26-274132:0
28,700 sharesCommon StockSEC:0001193125-26-274134:0
3,475 shares@ US$1.88280.0036% mcap41.9% of flowCommonSEC144:0001950047-26-005561
25 of 466 declarations
About Alector, Inc.
Alector, Inc. is a US healthcare and pharma company listed on Nasdaq, with a market capitalisation of USD 220.0 million and 7.4% of its capital held by insiders. Its record is almost entirely on the selling side: 236 sales worth EUR 155,244,762 (median EUR 117,495) against 7 purchases worth EUR 14,265,985, or 3% purchases among open-market trades. The three largest sales come from Orbimed Advisors LLC, a holder of more than 10%: EUR 32,709,271 on March 2, 2020, EUR 10,689,426 on December 17, 2019 and EUR 10,471,369 on March 2, 2020.
The purchases are concentrated on a single day, February 11, 2019, when 2 insiders bought for EUR 13,815,120: Orbimed Advisors LLC, EUR 3,409,318 for one purchase and EUR 2,649,923 for another, and Carl L. Gordon, director, EUR 3,409,318. These make up 6 grouped filings.
Read moreShow less
Out of 465 filings, Robert Paul, Chief Medical Officer, has 93, of which 56 sales, and Arnon Rosenthal, Chief Executive Officer, 46, of which 33 sales. Add 77 grants and 65 option exercises. The year 2021 peaks at 122 filings. The last twelve months hold 47, of which 21 sales and no purchase.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
